Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Autonomic dysfunction following COVID-19 infection: an early experience
Neuromuscular and Clinical Neurophysiology (EMG)
P18 - Poster Session 18 (5:30 PM-6:30 PM)
9-005

Post-COVID-19 syndrome is a poorly understood aspect of the current pandemic, with clinical features that overlap with symptoms of autonomic/small fiber dysfunction. 

We present an early systematic analysis of autonomic dysfunction following COVID-19 to provide initial insights into the spectrum of this condition.

We conducted a retrospective review of all patients with confirmed history of COVID-19 infection referred for autonomic testing for symptoms concerning for para-/postinfectious autonomic dysfunction at Mayo Clinic Rochester or Jacksonville between March 2020 and January 2021.

We identified 27 patients fulfilling the search criteria. Symptoms developed between 0 and 122 days following the acute infection and included lightheadedness (93%), orthostatic headache (22%), syncope (11%), hyperhidrosis (11%), and burning pain (11%). Sudomotor function was abnormal in 36%, cardiovagal function in 27%, and cardiovascular adrenergic function in 7%. The most common clinical scenario was orthostatic symptoms without tachycardia or hypotension (41%); 22% of patients fulfilled the criteria for postural tachycardia syndrome (POTS), and 11% had borderline findings to support orthostatic intolerance. One patient each was diagnosed with autoimmune autonomic ganglionopathy, inappropriate sinus tachycardia, vasodepressor syncope, cough/vasovagal syncope, exacerbation of preexisting orthostatic hypotension, exacerbation of sensory and autonomic neuropathy, and exacerbation of small fiber neuropathy.

Abnormalities on autonomic testing were seen in the majority of patients but were mild in most cases. The most common finding was orthostatic intolerance, often without objective hemodynamic abnormalities on testing. Unmasking/exacerbation of preexisting conditions was seen. The temporal association between infection and autonomic symptoms implies a causal relationship, which however cannot be proven by this study.

Authors/Disclosures
Kamal Shouman, MD (Mayo Clinic)
PRESENTER
The institution of Dr. Shouman has received research support from dysautonomia international.
No disclosure on file
William P. Cheshire, Jr., MD, FAAN (Mayo Clinic) Dr. Cheshire has received personal compensation in the range of $500-$4,999 for serving as a Consultant for oxford university press. Dr. Cheshire has a non-compensated relationship as a Associate Editor with Clinical Autonomic Research that is relevant to AAN interests or activities.
Mariana Suarez No disclosure on file
Shahar Shelly, MD (Rambam Medical Center) Dr. Shelly has nothing to disclose.
Guillaume Lamotte, MD Dr. Lamotte has nothing to disclose.
Paola Sandroni, MD, PhD, FAAN (Mayo Clinic) Dr. Sandroni has nothing to disclose.
Eduardo E. Benarroch, MD, FAAN (Mayo Clinic) Dr. Benarroch has nothing to disclose.
Sarah E. Berini, MD (Mayo Clinic) Dr. Berini has nothing to disclose.
Jeremy K. Cutsforth-Gregory, MD, FAAN (Mayo Clinic) Dr. Cutsforth-Gregory has received publishing royalties from a publication relating to health care.
Elizabeth A. Coon, MD, FAAN (Mayo Clinic) Dr. Coon has nothing to disclose.
Michelle L. Mauermann, MD, FAAN (Mayo Clinic) The institution of Dr. Mauermann has received research support from IONIS. The institution of Dr. Mauermann has received research support from Alnylam. Dr. Mauermann has received publishing royalties from a publication relating to health care.
Phillip A. Low, MD, FAAN (Mayo Clinic) Dr. Low has nothing to disclose.
Wolfgang Singer, MD (Mayo Clinic) Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UniQure. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance. The institution of Dr. Singer has received research support from NIH. The institution of Dr. Singer has received research support from FDA. The institution of Dr. Singer has received research support from Michael J. Fox Foundation. Dr. Singer has received intellectual property interests from a discovery or technology relating to health care.